![]() Developing multispecific drugs-based therapeutic agents have the potential not only to engage multiple therapeutic targets in disease pathways, but also to employ multiple modes of action and biological effectors. The multispecific biotherapeutics drug candidates have made up a significant portion of clinical and preclinical pipelines of large and small biopharmaceutical companies. As a response to these arduous tasks, the multispecific concept that targets two or more entities has been gradually picked up by the industry for the past decade. Disappointing clinical studies and significant unmet medical needs remain abundant. The conventional mono-targeting drug model developed in the 1970s has worked exceptionally well on those “low-hanging fruit” targets, yet its effectiveness has been challenged by the growing complexity of yet-to-be addressed human diseases. The rise of this innovation wave builds on the rational drug design principle harnessing the power of genomics, proteomics, and metabolomics. Novel therapeutic modalities such as RNA-based therapies, cell-based therapies, and gene-therapies are also available to patients who desperately need these medicines. Along with small-molecule entities, biotherapeutics drugs such as antibodies make up a significant portion of these approved new medicines. Biopharmaceutical innovation has entered a new age of prosperity with record-breaking approvals for new molecular entities and biologics by the US Food and Drug Administration for the past few years. ![]()
0 Comments
Leave a Reply. |